Results 231 to 240 of about 177,501 (382)

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

A fatal case of fulminant myocarditis after influenza infection with a rapidly progressive course: A case report

open access: yesIDCases
Myocarditis is an inflammation of the heart muscle. The most common cause of myocarditis is viral infections. clinical presentation of acute myocarditis is highly variable and varies from asymptomatic to fulminant heart failure or sudden death. Fulminant
Behnam Shakerian   +1 more
doaj  

Parvovirus B19 infection causing pure red cell aplasia in a recipient of pediatric donor kidneys [PDF]

open access: yes, 1993
Corral, DA   +8 more
core   +1 more source

Organoid Models to Study Human Infectious Diseases

open access: yesCell Proliferation, EarlyView.
Our manuscript reviews the role of organoids as models for studying human infectious diseases, highlighting their irreplaceable contributions to drug testing and vaccine development for significant infectious diseases including HIV, ZIKV, SARS‐CoV‐2 and MPXV.
Sijing Zhu   +4 more
wiley   +1 more source

Varicella myocarditis presenting with unusual ventricular arrhythmias. [PDF]

open access: bronze, 1977
G I Fiddler   +3 more
openalex   +1 more source

Role of Histone Deacetylase and Inhibitors in Cardiovascular Diseases

open access: yesCell Proliferation, EarlyView.
HDACs play an important role in the occurrence and development of cardiovascular diseases, such as myocardial hypertrophy, hypertension, and atherosclerosis. HDAC inhibitors have broad prospects for the treatment of CVD, and different HDAC subtypes can act through different mechanisms.
Li‐Ying Zhang   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy